Cargando…

Heterotopic caval valve implantation in severe tricuspid regurgitation

Severe symptomatic tricuspid regurgitation (TR) with right heart failure is associated with significant morbidity and mortality. Medical therapy is often ineffective and surgical correction is not feasible due to prohibitive perioperative risk. Transcatheter caval valve implantation (CAVI) is an evo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Neeraj Kumar, Chouhan, Nagendra Singh, Bansal, Manish, Chandra, Praveen, Singh, Ajmer, Juneja, Rajiv, Mehta, Yatin, Trehan, Naresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404582/
https://www.ncbi.nlm.nih.gov/pubmed/34269270
http://dx.doi.org/10.4103/aca.ACA_72_20
Descripción
Sumario:Severe symptomatic tricuspid regurgitation (TR) with right heart failure is associated with significant morbidity and mortality. Medical therapy is often ineffective and surgical correction is not feasible due to prohibitive perioperative risk. Transcatheter caval valve implantation (CAVI) is an evolving therapeutic option for this condition. It refers to the heterotopic placement of a valve into the inferior vena cava alone or with a second valve in the superior vena cava to restrict the backflow from the failing tricuspid valve. We hereby describe a patient with previous mitral valve surgery with chronic severe TR who underwent successful CAVI at our institute.